On a mission to
transform the future
of autoimmune care

Developing innovative therapies with the potential to redefine
the standard of care for autoimmune diseases.

Who We Are

Jade
Biosciences

We are a clinical-stage company developing a pipeline of potentially best-in-class therapies aimed at transforming the standard of care for patients living with autoimmune diseases. Our programs build on discovery-stage assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.

Jade’s lead candidate, JADE101, is designed to inhibit the cytokine APRIL (A PRoliferation-Inducing Ligand) and is being developed for the treatment of immunoglobulin A nephropathy (IgAN).

Explore Pipeline →